In 2019, the development momentum of pharmaceutical professional equipment in the sub-sector of the pharmaceutical industry is slow

[ Focus on Chemical Machinery and Equipment Network ] National* data shows that in 2019, China's pharmaceutical industry achieved a cumulative revenue of 2390.
86 billion yuan, a year-on-year growth rate of 7.
4%; the industry achieved a net profit of 33.
95 billion yuan, a year-on-year increase of 5.
9%.

 

It is understood that the pharmaceutical industry can be further divided into eight sub-industries such as chemical raw materials, chemical preparations, Chinese herbal medicines, biological drugs, medical equipment, professional pharmaceutical equipment, sanitary materials and medical supplies, pharmaceutical excipients and packaging materials.

 

Among the eight sub-industries, the growth rate of revenue and net profit attributable to the parent industry in the sub-sectors of chemical raw materials, chemical drug preparations, Chinese herbal medicines, biological drugs, and medical devices in 2019 are relatively obvious, with an increase of more than 10%.

 

Among them, the growth rate of revenue and net profit attributable to the parent in the chemical preparation industry in 2019 were 12.
4% and 12.
7%, respectively.
In recent years, under the promotion of policies such as consistency evaluation, the reform of the supply side of generic drugs has accelerated, forcing the structural transformation of the industry from generic drugs to innovative drugs.
The industry expects that the differentiation of chemical drug companies will be more obvious in the future.

 

　　The growth rate of revenue and net profit attributable to the parent drug industry in 2019 were 14.
3% and 17.
6%, respectively.
With the pressure of environmental protection policies, the API industry is forced to upgrade.
At the same time, with the introduction of policies such as consistency evaluation, volume procurement and related review, the status of APIs in the pharmaceutical industry chain is continuously strengthened, and the specialty API industry will grow in the future.
The space is expected to open further.

 

　　The revenue growth rate and net profit growth rate of the Chinese medicine industry in 2019 were 13.
9% and -4.
5%, respectively.
It is understood that in 2019, the traditional Chinese medicine industry is greatly affected by medical insurance control fees, and internal differentiation is serious.
For example, traditional Chinese medicine injections are affected by policies such as medical insurance restrictions on hospitals below the second level, and their use is continuously restricted.
In addition, other oral Chinese patent medicines are also facing the pressure of strict supervision of large varieties and price reductions in bidding.
The industry believes that in the short term, there is greater pressure on the inventory of Chinese medicine channels, but the growth logic remains unchanged, and changes in the policy of Chinese medicine injections still need to be observed.

 

　　The growth rate of revenue and net profit attributable to the parent of the biopharmaceutical industry in 2019 were 23.
4% and 12.
3%, respectively.
In recent years, the overall revenue of the biological products industry has grown steadily and rapidly, and the growth rate is higher than that of other small molecule industries.
Biological products, especially blood products and vaccines, are less affected by the policy.
Among them, blood product resources have obvious attributes, and the industry is less affected by policies such as medical insurance control fees; while vaccines are partial to consumption attributes, and the annual demand for a type of vaccine is stable.
The second type of vaccine has benefited from the increase in public health awareness in recent years, consumption upgrades, and the increase in vaccination and penetration rates, and the profits of the vaccine industry have increased significantly.

 

　　In addition, the medical device industry's revenue growth rate and parent net profit growth rate in 2019 were 15.
9% and 19.
3%, respectively.
In recent years, with the continuous improvement of domestic medical device product technology, coupled with *import advantages, domestic medical devices have a huge space to replace imports.
With the merger and reorganization of domestic enterprises, the comprehensive competitiveness of domestic medical devices is expected to continue to improve, and the development prospects broad.

 

　　Compared with other sub-industries, the development momentum of pharmaceutical professional equipment appears to be relatively slow.
As the "mother machine" of pharmaceutical production, pharmaceutical equipment is indispensable.
With consumption upgrades and aging, the demand for the pharmaceutical market will continue to expand.
It can be foreseen that the pharmaceutical equipment industry will have a relatively large room for development in the future.

 

　　It is understood that due to rising labor costs and rising raw material prices, pharmaceutical equipment manufacturers are facing certain pressure to control costs.
At the same time, with the fierce market competition, in order to enhance market competitiveness, pharmaceutical machinery companies need to continuously improve the technological content and product quality of their products, which have to invest a lot of research and development expenses, and small and medium-sized enterprises are under obvious pressure.

 

　　From an overall point of view, due to the obvious gap between the quality and technical content of pharmaceutical products, the overall profit margin of the industry varies greatly.
With the current acceleration of the pharmaceutical industry's upgrading, pharmaceutical equipment urgently needs to be transformed from the low-end to break the import monopoly, and meet the renewal demand of pharmaceutical companies for equipment, so as to seize the opportunity for development.

 

　　Original title: The development status of the pharmaceutical industry in 2019: the development of professional pharmaceutical equipment in the sub-industry is slow